A protein implicated in the development of vascular diseases may also contribute to the failure of arteriovenous (AV) fistulas created for vascular access in dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
“Our findings raise the possibility that monocyte chemoattractant protein-1 (MCP-1) may contribute to the relatively poor outcomes regarding the function and longevity of human hemodialysis AV fistulas,” comments Karl A. Nath, MB.ChB (Mayo Clinic, Rochester, MN).
AV fistulas are the preferred form of access to the circulatory system in dialysis patients. They are created by a surgical procedure to connect a vein to an artery, usually in the lower arm. The use of AV fistulas, compared to other types of dialysis access, leads to fewer complications such as infections, less hospitalization of dialysis patients, and overall, a better outcome for the dialysis patient.
However, AV fistulas are prone to certain problems. About half of AV fistulas never become functional for use in dialysis, while those that do become functional have a significant failure rate. “We thus need to understand why AV fistulas do not develop, or fail to function after a relatively short period of use,” says Nath.
In a series of experiments in mice, the researchers found that MCP-1 — an inflammation-promoting chemokine protein — was a “critical contributor” to AV fistula failure. The failing fistulas showed increased levels of MCP-1, and of the gene that encodes it. In contrast, AV fistulas functioned much better in genetically altered mice that lacked
MCP-1. In the absence of MCP-1, AV fistulas had less vein wall thickening, and the number of functional AV fistulas was substantially higher.
Take-away message: “The present study is the first
to directly demonstrate that
MCP-1 critically contributes to failure of an AV fistula,” the researchers write. The results are timely, because drugs that act as MCP-1 blockers are currently under development. “Such agents, when clinically available, may be considered as a possible therapeutic approach to promote the maturation of AV fistulas, and/or extend their duration of function,” says Nath.
The researchers emphasize that more research will be needed to confirm whether the results of these animal experiments are relevant to AV fistulas in humans.
Co-authors on the study include Julio Juncos, MD, Lu Kang, MD, Allan Ackerman, MS, and Anthony Croatt, BS (Mayo Clinic, Division of Nephrology and Hypertension); Joseph Grande, MD, PhD (Mayo Clinic College of Medicine, Department of Pathology) and Zvonimir Katusic, MD, PhD (Mayo Clinic College of Medicine, Department of Anesthesiology and Molecular Pharmacology and Experimental Therapeutics).
This study was supported by grants from the National Institutes of Health (DK70124 and DK47060). The authors reported no financial disclosures.
The article, entitled “MCP-1 Contributes to Arteriovenous Fistula Failure” is currently online at http://jasn.asnjournals.org, doi 10.1681/ASN.2010040373.
The American Society of Nephrology (ASN) does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966 and comprised of more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.